The Antidote To Competition: Portola’s Rivals Fund Study On Class-Wide Anticoagulant Antidote
This article was originally published in The Pink Sheet Daily
Although one day it may compete with Bristol-Myers Squibb and Pfizer in the market for anticoagulant Factor Xa inhibitors, Portola has partnered with the two pharmas to fund a study on its class-wide antidote compound that prevents serious bleeding events.
You may also be interested in...
Breakthrough drug andexanet alfa meets all endpoints for reversing effects of Bristol/Pfizer’s Eliquis in Phase III, bringing the company a step closer to a filing for an accelerated approval by year’s end.
At a time when demand for anticoagulant antidotes is high, the 2013 AHA meeting featured the first human data for two new reversal agents from Boehringer Ingelheim and Perosphere. Perosphere will be pursuing “breakthrough therapy” status with FDA for its intravenous small molecule candidate PER977.
Despite pricing well below its range and trading down, Ambit could raise $90 million in an IPO and a private placement with existing investors. Also this week, gene therapy company bluebird bio filed for an IPO, and hematology play Portola made the rounds on its investor road show.